Viridian Therapeutics, Inc.\DE (VRDN) Capital Expenditures (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Capital Expenditures history runs 13 years deep, the most recent figure standing at $23000.0 for Q1 2026.

• In Q1 2026, Capital Expenditures fell 73.26% year-over-year to $23000.0; the TTM figure through Mar 2026 stood at $432000.0 (down 27.64% YoY), while the FY2025 annual figure was $495000.0, down 3.13% from the prior year.
• Capital Expenditures for Q1 2026 stood at $23000.0, down from $240000.0 in the prior quarter.
• The five-year high for Capital Expenditures was $566000.0 in Q3 2022, with the low at -$186000.0 in Q4 2022.
• The 5-year median for Capital Expenditures is $114500.0 (2023), against an average of $144187.5.
• The sharpest annual moves came in 2022 and 2023: Capital Expenditures plunged 359.42% in 2022, then jumped 284.92% in 2023.
• Viridian Therapeutics, Inc.\DE's Capital Expenditures stood at -$186000.0 in 2022, then soared by 125.81% to $48000.0 in 2023, then jumped by 137.5% to $114000.0 in 2024, then soared by 110.53% to $240000.0 in 2025, then tumbled by 90.42% to $23000.0 in 2026.
• Business Quant data shows VRDN's Capital Expenditures at $23000.0 in Q1 2026, $240000.0 in Q4 2025, and $127000.0 in Q3 2025.